The financing alleviates near-term liquidity concerns and funds the critical ELPIS II readout, but the high potential dilution and milestone dependency introduce risk. Traders should monitor the Q3 2026 data readout and any updates on PRV eligibility or second tranche triggers.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 12 $0.8090entry
- T+1 · 8mo ago +20.40%α +20.99% · $0.9740
- T+5 · 8mo ago +37.21%α +38.19% · $1.11
- T+20 · 7mo ago +43.39%α +41.41% · $1.16
- T+60 · 5mo ago −9.77%α −20.46% · $0.7300
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Longeveron (LGVN) closed the first tranche of a $30 million private placement, raising $15 million upfront through a mix of common and convertible preferred stock issued at $0.52 per share. Proceeds extend the company's cash runway into Q4 2026, covering the pivotal Phase 2b ELPIS II trial readout for HLHS in Q3 2026. An additional $15 million is contingent on clinical milestones and share price performance.
Key Financial Metrics
Key Facts
- Raised $15 million in initial tranche of private placement, with up to $15 million more contingent on milestones.
- Issued 6,013,384 Class A common shares and Series A Preferred Shares convertible into 22,832,770 common shares, all priced at $0.52 per share.
- Cash runway extended into Q4 2026, past the ELPIS II trial topline data readout in Q3 2026.
- Investors include Coastlands Capital, Janus Henderson Investors, Logos Capital, and Kalehua Capital.
- Investors receive 50% of proceeds from potential Rare Pediatric Disease Priority Review Voucher (PRV) sale.
- H.C. Wainwright & Co. acted as exclusive placement agent; registration rights granted for resale.
Financial Impact
$15 million immediate capital raise, with $15 million milestone-dependent. Total potential dilution from conversion: ~28.8 million new shares (478% of current ~6M float).
Risk Factors
- High dilution: conversion of preferred shares would increase share count by ~478%.
- Second tranche is not guaranteed, dependent on clinical trial results and share price.
- No assurance of PRV issuance or monetization, which underpins part of the investor return structure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254131 |
Track record
22 reports on LGVN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers